Important cutaneous manifestations of inflammatory bowel disease

Postgraduate Medical Journal

Volumn 81, Issue 959, 2005, Pages 580-585

  Trost, L B ^a   McDonnell, J K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMLEXANOX; ANALGESIC AGENT; AZATHIOPRINE; BROMIDE; CLOFAZIMINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; INDOMETACIN; INFLIXIMAB; IODIDE; METHYLPREDNISOLONE; MINOCYCLINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PENICILLIN DERIVATIVE; POTASSIUM IODIDE; SALAZOSULFAPYRIDINE; SULFAMETHOXYPYRIDAZINE; SULFAPYRIDINE; SULFONAMIDE; TACROLIMUS; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

APHTHOUS STOMATITIS; DISEASE COURSE; ENTERITIS; ERYTHEMA NODOSUM; HUMAN; PYODERMA GANGRENOSUM; PYOSTOMATITIS VEGETANS; REVIEW; SKIN MANIFESTATION; SKIN NODULE; SKIN ULCER; SUPERINFECTION;

ERYTHEMA NODOSUM; HUMANS; INFLAMMATORY BOWEL DISEASES; MOUTH DISEASES; PYODERMA GANGRENOSUM;

EID: 24744445759     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.031633     Document Type: Review

References (64)

1. Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:1-20.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
3. Danzi JT. Extraintestinal manifestations of idiopathic inflammatory bowel disease. Arch Intern Med 1988;148:297-302.
4. Berkowitz EZ, Lebwohl M. Cutaneous manifestations of inflammatory bowel disease. J Eur Acad Dermatol Venereol 2000;15:349-50.
5. Greenstein AJ, Janowiz HD, Sachar DB. The extraintestinal manifestations of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55:401-12.
6. Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992;26:371-83.
7. Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm Bowel Dis 1998;4:142-8.
8. Powell FC, Su WRD, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34:395-409.
9. Bennett M, Jackson J, Jorizzo J, et al. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine 2000;79:37-46.
10. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002;3:149-58.
11. Boh EE, Faleh al-Smadi RM. Cutaneous manifestations of gastrointestinal diseases. Dermatol Clin 2002;20:533-46.
12. Schwaegerle SM, Bergfeld WF, Senitzer D, et al. Pyoderma gangrenosum: a review. J Am Acad Dermatol 1988;18:559-68.
13. Schorr-Lesnick B, Brandt LJ. Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988;83:216-23.
14. Chow R, Ho V. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996;34:1047-60.
15. Powell F, O'Kane M. Management of pyoderma gangrenosum. Dermatol Clin 2002;20:347-55.
16. Tamir A, Landau M, Brenner S. Topical treatment with 1% sodium cromoglycate in pyoderma gangrenosum. Dermatology 1996;192:252-4.
17. Lyon C, Smith A, Griffiths C, et al. Peristomal dermatoses: a novel indication for topical steroids. J Am Acad Dermatol 2000;43:679-82.
18. Goldstein F, Krain R, Thornton J. Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol 1985;7:499-501.
19. Jennings J. Pyoderma gangrenosum: successful treatment with intralesional steroids. J Am Acad Dermatol 1983;9:575-80.
20. Powell FC, Collins S. Pyoderma gangrenosum. Clin Dermatol 2000;18:283-93.
21. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease: a prospective study or 792 patients. J Clin Gastroenterol 1996;23:29-34.
22. Matis WL, Ellis CN, Griffiths CEM. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992;128:1060-4.
23. O'Donnell B, Powell FC. Cyclosporin treatment of pyoderma gangrenosum. J Am Acad Dermatol 1991;24:141-3.
24. Curley R, MacFarlane A, Vickers C. Pyoderma gangrenosum treated with cyclosporin A. Br J Dermatol 1985;113:601-4.
25. Penmetcha M, Navartnam AE. Pyoderma gangrenosum, response to cyclosporin A. Int J Dermatol 1988;27:253.
26. Bijlmer-Iest J, Rompelman-Schiere S, Van Ginkel C. Treatment of pyoderma gangrenosum with cyclosporin. Br J Dermatol 1991;135:283.
27. Schmitt EC, Pigatto PD, Boneschi V, et al. Pyoderma gangrenosum treated with low-dose cyclosporin. Br J Dermatol 1993;128:230-1.
28. Capella G, Frigerio E, Fracchiolla C, et al. The simultaneous treatment of inflammatory bowel diseases and associated pyoderma gangrenosum with oral cyclosporin A. Scand J Gastroenterol 1999;34:220-1.
29. Tutuncu Z, Morgan G, Kavanaugh A. Anti-TNF therapy for other inflammatory conditions. Clin Exp Rheumatol 2002;20:S146-51.
30. Grange F, Djilali-Bouzina F, Weiss A, et al. Corticosteroid-resistant pyoderma gangrenosum associated with Chrohn's disease: Rapid cure with infliximab. Dermatology 2002;205:278-80.
31. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn disease: Effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002;37:1108-10.
32. Triantafillidis J, Cheracakis P, Sklavaina M, et al. Favorable response to infliximab treatment in a patient with active Crohn disease with pyoderma gangrenosum. Scand J Gastroenterol 2002;37:863-5.
33. Tan M, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001;137:930-3.
34. Hughes A, Jackson J, Callen J. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000;284:1546-8.
35. Levift M, Ritchie J, Lennard-Jones J, et al. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 1991;78:676-8.
36. Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 1985;80:615-20.
37. While JW. Erythema nodosum. Dermatol Clin 1985;3:119-27.
38. Requena L, Requena C. Erythema nodosum. Dermatology Online Journal 2002;8:4.
39. Helm T. Skin lesions: when to suspect systemic causes. Cleve Clin J Med 1993;60:104.
40. Gonzales-Gay MA, Garcia-Porrua C, Pujol RM, et al. Erythema nodosum: a clinical approach. Clin Exp Rheumatol 2001;19:365-8.
41. Apgar JT. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin Dermatol 1991;10:138-47.
42. Fox MD, Schwartz RA. Erythema nodosum. Am Fam Physician 1992;46:818-22.
43. Bullock WE. The clinical significance of erythema nodosum. Hosp Pract 1986;21:102E-102X.
44. Brodell RT, Mehrabi D. Underlying causes of erythema nodosum-lesions may provide clue to systemic disease. Postgrad Med 2000;108:147-9.
45. Lehman CW. Control of erythema nodosum with naproxen. Cutis 1980;26:66-7.
46. Ubogy Z, Persellin R. Suppression of erythema nodosum by indomethacin. Acta Derm Venereol 1982;62:265-6.
47. Elizaga FV. Erythema nodosum and indomethacin. Ann Intern Med 1982;96:383.
48. Horio T, Imamura S, Danno K, et al. Potassium iodide in the treatment of erythema nososum and nodular vasculitis. Arch Dermatol 1981;117:29-31.
49. Horio T, Danno K, Okamoto H, et al. Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol 1983;9:77-81.
50. Schulz EJ, Whiting DA. Treatment of erythema nodosum and nodular vasculitis with potassium iodide. Br J Dermatol 1976;94:75-8.
51. MacPhail L. Topical and systemic therapy for recurrent aphthous stomatitis. Seminars Cutaneous Medicine and Surgery 1997;16:301-7.
52. Shashy R, Ridley M. Aphthous ulcers: a difficult clinical entity. Am J Otolaryngol 2000;21:389-93.
53. Zunt S. Recurrent aphthous stomatitis. Dermatol Clin 2003;21:33-9.
54. McBride D. Management of aphthous ulcers. Am Fam Physician 2000;62:149-54.
55. Holme L, Meurman J, Laine P, et al. Oral findings in patients with active or inactive Crohn's disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1993;76:175-81.
56. Plauth M, Jenss H, Meyle J. Oral manifestations of Crohn's disease: an analysis of 79 cases. J Clin Gastroenterol 1991;13:29-37.
57. Lisciandrano D, Ranzi T, Carrassi A, et al. Prevalence of oral lesions in inflammatory bowel disease. Am J Gastroenterol 1996;91:7-10.
58. Williams A, Wray D, Ferguson A. The clinical entity of orofacial Crohn's disease. Q J Med 1991;79:451-8.
59. Soriano M, Martinez N, Grilli R, et al. Pyodermatitis-pyostomatitis vegetans: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:322-6.
60. Calobrisi S, Mutasim D, McDonald J. Pyostomatitis vegetans associated with ulcerative colitis: temporary clearance with fluocinonide gel and complete remission after colectomy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:452-4.
61. Brinkmeier T, Frosch P. Pyodermatitis-pyostomatitis vegetans: a clinical course of two decades with response to cyclosporine and low-dose prednisone. Acta Derm Venereol 2001;81:134-6.
62. Chaudhry S, Philpot N, Odell E, et al. Pyostomatitis vegetans associated with asymptomatic ulcerative colitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;1999:327-30.
63. Storwick G, Prihoda M, Fulton R, et al. Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. J Am Acad Dermatol 1994;31:336-41.
64. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci 1999;44:1-13.